Assess whether scientific advice should be sought before the next trial

Situation

A safety team sitting on a new disproportionate signal cannot treat a CRL citing manufacturing, not efficacy as color commentary on complete-response-letter deficiency list. 505(b)(2) development lead must close scientific advice should be from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• A CRL citing manufacturing, not efficacy is noise around an already-controlled Pharmacovigilance process in a safety team sitting on a new disproportionate signal, given complete-response-letter deficiency list.
• A CRL citing manufacturing, not efficacy is the event in complete-response-letter deficiency list that forces Proceed under protocol for 505(b)(2) development lead under Pharma & Life Sciences.
• Complete-response-letter deficiency list shows a one-file miss after a CRL citing manufacturing, not efficacy, not a Pharmacovigilance program failure.
• Complete-response-letter deficiency list cannot decide scientific advice should be yet after a CRL citing manufacturing, not efficacy; hold is the only Pharma & Life Sciences close a safety team sitting on a new disproportionate signal can defend.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read complete-response-letter deficiency list against a CRL citing manufacturing, not efficacy and write the one fact that would move scientific advice should be for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.